Gemfibrozil

Gemfibrozil

1. This product can significantly enhance the effect of oral anticoagulants. When used with it, attention should be paid to reducing the dose of oral anticoagulants and frequently monitoring the prothrombin time to adjust the dose of anticoagulants. Its mechanism of action is still uncertain. It may be because this product can replace warfarin and other drugs from their protein binding sites, thereby enhancing their effects. 2. When this product is used in combination with other drugs with high protein binding rates, it can also replace them from the protein binding sites, leading to enhanced effects, such as tolbutamide and other sulfonylurea hypoglycemic drugs, phenytoin, furosemide, etc. When taking the above drugs during lipid-lowering treatment, the doses of hypoglycemic drugs and other drugs should be adjusted. 3. The combined use of clofibric acid derivatives and HMG-CoA reductase inhibitors, such as lovastatin, for the treatment of hyperlipidemia will increase the risk of severe muscle toxicity of both, which can cause myalgia, rhabdomyolysis, increased blood creatine phosphokinase and other myopathy, and should be avoided as much as possible. 4. When this product is used in combination with bile acid binding resins, such as colestipol, gemfibrozil should be taken at least 2 hours before or 2 hours after taking these drugs. Bile acid binding drugs can bind to other drugs taken at the same time, thereby affecting the absorption of other drugs. 5. This product is mainly excreted through the kidneys. When used in combination with immunosuppressants, such as cyclosporine, it can increase the latter's blood concentration and nephrotoxicity, and there is a risk of worsening renal function. The dose should be reduced or the drug should be discontinued. Caution should also be exercised when this product is used in combination with other nephrotoxic drugs.

Gemfibrozil

1. This product can significantly enhance the effect of oral anticoagulants. When used with it, attention should be paid to reducing the dose of oral anticoagulants and frequently monitoring the prothrombin time to adjust the dose of anticoagulants. Its mechanism of action is still uncertain. It may be because this product can replace warfarin and other drugs from their protein binding sites, thereby enhancing their effects. 2. When this product is used in combination with other drugs with high protein binding rates, it can also replace them from the protein binding sites, leading to enhanced effects, such as tolbutamide and other sulfonylurea hypoglycemic drugs, phenytoin, furosemide, etc. When taking the above drugs during lipid-lowering treatment, the doses of hypoglycemic drugs and other drugs should be adjusted. 3. The combined use of clofibric acid derivatives and HMG-CoA reductase inhibitors, such as lovastatin, for the treatment of hyperlipidemia will increase the risk of severe muscle toxicity of both, which can cause myalgia, rhabdomyolysis, increased blood creatine phosphokinase and other myopathy, and should be avoided as much as possible. 4. When this product is used in combination with bile acid binding resins, such as colestipol, gemfibrozil should be taken at least 2 hours before or 2 hours after taking these drugs. Bile acid binding drugs can bind to other drugs taken at the same time, thereby affecting the absorption of other drugs. 5. This product is mainly excreted through the kidneys. When used in combination with immunosuppressants, such as cyclosporine, it can increase the latter's blood concentration and nephrotoxicity, and there is a risk of worsening renal function. The dose should be reduced or the drug should be discontinued. Caution should also be exercised when this product is used in combination with other nephrotoxic drugs.

Gemfibrozil

1. This product can significantly enhance the effect of oral anticoagulants. When used with it, attention should be paid to reducing the dose of oral anticoagulants and frequently monitoring the prothrombin time to adjust the dose of anticoagulants. Its mechanism of action is still uncertain. It may be because this product can replace warfarin and other drugs from their protein binding sites, thereby enhancing their effects. 2. When this product is used in combination with other drugs with high protein binding rates, it can also replace them from the protein binding sites, leading to enhanced effects, such as tolbutamide and other sulfonylurea hypoglycemic drugs, phenytoin, furosemide, etc. When taking the above drugs during lipid-lowering treatment, the doses of hypoglycemic drugs and other drugs should be adjusted. 3. The combined use of clofibric acid derivatives and HMG-CoA reductase inhibitors, such as lovastatin, for the treatment of hyperlipidemia will increase the risk of severe muscle toxicity of both, which can cause myalgia, rhabdomyolysis, increased blood creatine phosphokinase and other myopathy, and should be avoided as much as possible. 4. When this product is used in combination with bile acid binding resins, such as colestipol, gemfibrozil should be taken at least 2 hours before or 2 hours after taking these drugs. Bile acid binding drugs can bind to other drugs taken at the same time, thereby affecting the absorption of other drugs. 5. This product is mainly excreted through the kidneys. When used in combination with immunosuppressants, such as cyclosporine, it can increase the latter's blood concentration and nephrotoxicity, and there is a risk of worsening renal function. The dose should be reduced or the drug should be discontinued. Caution should also be exercised when this product is used in combination with other nephrotoxic drugs.